Current Report Filing (8-k)
December 08 2016 - 11:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2016
Five Prime Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36070
|
|
26-0038620
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
Two Corporate Drive
South San Francisco, California
|
|
94080
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (415)
365-5600
(Former name
or former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On December 8, 2016, Five Prime Therapeutics, Inc.
(“FivePrime”) held its Research & Development Day event in New York, New York, during which FivePrime reviewed (i) its therapeutic candidate programs in which
IND-enabling
activities
have begun, (ii) activities and progress in its immuno-oncology discovery and early research efforts and (iii) the status of its clinical development programs (the “Presentation”). A copy of the slides FivePrime presented during
the Presentation is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference.
The information provided in this Form
8-K,
including Exhibit 99.1 hereto, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Slide deck presented by FivePrime on December 8, 2016
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Five Prime Therapeutics, Inc.
|
|
|
|
|
By:
|
|
/s/ Francis Sarena
|
|
|
|
Francis Sarena
|
|
|
|
Chief Strategy Officer and Secretary
|
Dated: December 8, 2016
3
EXHIBIT INDEX
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
99.1
|
|
Slide deck presented by FivePrime on December 8, 2016
|
4
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
